SkinBioTherapeutics (LON:SBTX) Issues Quarterly Earnings Results

SkinBioTherapeutics (LON:SBTX) posted its quarterly earnings data on Monday. The company reported GBX (0.31) EPS for the quarter, Digital Look Earnings reports. SkinBioTherapeutics had a negative return on equity of 10.01% and a negative net margin of 15.01%.The business had revenue of GBX 217 million for the quarter.

SkinBioTherapeutics Stock Performance

Shares of SBTX opened at GBX 9.75 on Monday. The business has a fifty day moving average of GBX 9.73 and a 200 day moving average of GBX 12.80. The firm has a market capitalization of £25.27 million, a P/E ratio of -31.45 and a beta of 0.47. SkinBioTherapeutics has a one year low of GBX 5 and a one year high of GBX 27.50. The company has a debt-to-equity ratio of 10.55, a current ratio of 4.84 and a quick ratio of 10.01.

SkinBioTherapeutics Company Profile

SkinBioTherapeutics plc, a life science company, engages in identification and development of technology that harnesses the human microbiome to improve health in the United Kingdom, the United States, and Europe. It develops SkinBiotix technology that promotes skin health by harnessing the beneficial properties of probiotic bacteria and the active components; and AxisBiotix technology that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis. The company has an agreement with Croda Plc; and operates two research programmes with the University of Manchester, an oral programme and an inflammation study.